The newest genetic research linking GLP-1 biology to hair loss could only be run in men, and that limitation now sits awkwardly beside the federal drug labels. In the clinical trials that supported approval of Zepbound, hair loss was reported by 7.1% of female patients compared with 0.5% of male patients, according to the tirzepatide prescribing information. Wegovy's label also lists hair loss among adverse reactions, reported by about 3% of adults taking the 2.4 mg dose compared with about 1% on placebo.
Researchers at NYU Langone Health reported that men carrying genetic variants tied to higher GLP-1 receptor activity had roughly a 7% added risk of male pattern baldness. The analysis, published online in early September in the Journal of Investigative Dermatology, was restricted to men because the genetics of male hair loss are far better mapped than the female equivalent. MedicalDaily reported on that genetic finding and what it does not show when the study was released.
That leaves a practical gap for the group most likely to raise the issue in an exam room. Survey data cited alongside the research indicate that about 12% of Americans have used a GLP-1 drug solely for weight loss, including roughly one in five women aged 50 to 64. Women are the larger share of the weight loss prescribing market and the larger share of reported shedding, yet the strongest new biological evidence does not describe them.
The Sex Split Sitting Inside the Drug Labels
The label figures are not estimates drawn from social media. They come from pooled randomized trial data submitted to the Food and Drug Administration, and they are specific. For Zepbound, the placebo comparison was 1.3% in women and zero in men. No patient taking Zepbound stopped the drug because of hair loss in the pooled dataset.
The label attributes those reports to weight reduction rather than to a direct effect on the follicle. That framing matters, because it points toward a reversible process rather than permanent damage. It also means the labeled rate reflects how much weight a patient lost and how quickly, not simply that they took the drug.
Pharmacovigilance data point in the same direction. A disproportionality analysis of FDA adverse event reports covering 2016 through 2025 examined seven GLP-1 receptor agonists and found statistically significant alopecia signals only for semaglutide and tirzepatide. The authors were explicit that spontaneous reporting systems cannot establish causation or estimate how often the problem actually occurs.
Telogen Effluvium Explains Most Shedding, but Not Every Case
The condition most clinicians describe in these patients is telogen effluvium, a temporary shift in the hair growth cycle triggered by rapid weight loss, illness, surgery, or nutritional shortfall. Shedding typically becomes noticeable two to four months after the trigger and resolves once weight stabilizes. Hair is not lost permanently, and the follicle stays intact.
Androgenetic alopecia is a different process. It is inherited, progressive, and in men follows a pattern along the top and front of the scalp. The NYU work suggests GLP-1 receptor activity, and that inherited pattern shares some biology, which would help explain why a subset of men might see thinning that does not simply reverse.
It is worth being clear about what the new study is. It is a two-sample Mendelian randomization analysis built on large public genetic databases, including one drawn from 31,684 men and women and another from 205,327 mostly White men. It did not follow anyone taking a prescription, and it did not measure how often shedding happens. Neither explanation has been tested in women taking these drugs, and female pattern hair loss involves diffuse thinning rather than a receding line.
Senior investigator Lynn Petukhova framed the eventual goal as a screening step, saying in a summary of the study from NYU Langone that "if future experiments prove successful, some men, and possibly women too, could be screened and benchmarked for their risk of hair loss before being prescribed GLP-1 medications." That step does not exist in clinical practice today.
Two NYU co-investigators on the study have previously served as investigators for hair loss drugs and devices made by Pfizer and Regen Labs, and one is a paid consultant to several companies, including Pfizer and Lilly. Those relationships are managed under NYU Langone policy. The study itself was funded by the National Institutes of Health.
Practical Steps Before Changing Anything
Nobody should stop a prescribed diabetes or obesity medication because of a genetics paper or a label footnote. The clinically useful move is to bring the timeline to a clinician: when the medication started, when shedding was first noticed, how fast weight came off, and whether anyone in the family has a history of pattern hair loss.
Bloodwork is often the next reasonable question. Rapid appetite suppression can lower intake of protein, iron, zinc, and vitamin D, all of which affect hair growth, and a prescriber can check whether that is contributing. Slowing the rate of weight loss is sometimes an option worth discussing.
Anyone considering a hair loss treatment should raise it with a dermatologist rather than an online seller. Minoxidil has the strongest evidence base for pattern hair loss, but no combination protocol has been tested or approved specifically for people taking GLP-1 medications, and that remains a research proposal rather than standard care.
What stays unknown is whether the genetic relationship found in men exists in women at all, how much of the label-reported shedding in women is pattern hair loss unmasked by weight loss rather than temporary effluvium, and whether the FDA will require further labeling changes. Petukhova has said she plans to investigate the question in women.
Federal regulators have not changed prescribing guidance, and the labeled rate remains well under one in ten patients. For most people, the realistic expectation is temporary thinning that improves as weight stabilizes. For the minority whose shedding does not improve, the evidence base is still thinner for women than for men, which is a reason to document the pattern early rather than a reason to stop treatment.
Key Questions Answered
Is hair loss actually on the FDA label for these drugs? Yes. The Zepbound and Wegovy prescribing information both list hair loss among adverse reactions. Zepbound's label reports a sex breakdown and attributes the reports to weight reduction.
Why does the new genetic study only cover men? Male pattern baldness has been studied far more extensively at the genetic level, so the databases needed for the analysis exist for men and not for women.
Does the research prove GLP-1 drugs cause hair loss in women? No. It did not include women, did not follow patients on prescriptions, and did not measure how often shedding occurred.
How long does GLP-1-related shedding usually last? When the cause is telogen effluvium tied to rapid weight loss, hair growth commonly resumes within several months after weight stabilizes.
Should someone stop their medication over hair thinning? No. Prescribing guidance has not changed, and stopping a diabetes or obesity medication without clinical advice carries its own risks.
What can a clinician actually check? Timing relative to the prescription, rate of weight loss, family history of pattern hair loss, and nutritional markers such as iron, zinc, protein, and vitamin D.
Is minoxidil an approved fix for this? Minoxidil is established for pattern hair loss generally, but no protocol has been tested or approved specifically for people taking GLP-1 medications.
